ArticleFrontiers in immunology2020
CD226 Deletion Reduces Type 1 Diabetes in the NOD Mouse by Impairing Thymocyte Development and Peripheral T Cell Activation.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2026Review
- The Immune Regulatory Functions of CD226 and Its Implications in Immune-Mediated Diseases.Biomolecules · 2025Review
- Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory T cells and diminishing effector T cell function.Diabetologia · 2025Article
- The perfect storm: unraveling the interplay of genetic predisposition and viral triggers in type 1 diabetes pathogenesis.Frontiers in endocrinology · 2025Review
- TGF-β-mediated crosstalk between TIGITNature communications · 2024Article
- Advancing Animal Models of Human Type 1 Diabetes.Cold Spring Harbor perspectives in medicine · 2024Review
- CD226 implicated in Akt-dependent apoptosis of CD4Cell death & disease · 2024Article
- Inhibition of CD226 Co-Stimulation Suppresses Diabetes Development in the NOD Mouse by Augmenting Tregs and Diminishing Effector T Cell Function.bioRxiv : the preprint server for biology · 2024Article
- Prevalence of Selected Polymorphisms of Il7R, CD226, CAPSL, and CLEC16A Genes in Children and Adolescents with Autoimmune Thyroid Diseases.International journal of molecular sciences · 2024Article
- TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes.Frontiers in immunology · 2024Article
- Treg-Specific CD226 Deletion Reduces Diabetes Incidence in NOD Mice by Improving Regulatory T-Cell Stability.Diabetes · 2023Article
- Genome-wide aggregated trans-effects on risk of type 1 diabetes: A test of the "omnigenic" sparse effector hypothesis of complex trait genetics.American journal of human genetics · 2023Article
- Activation pathways that drive CD4Immunological reviews · 2022Review
- Review
- Human CD4Frontiers in immunology · 2022Article
- T cell transgressions: Tales of T cell form and function in diverse disease states.International reviews of immunology · 2022Review
- Functional Impact of Risk Gene Variants on the Autoimmune Responses in Type 1 Diabetes.Frontiers in immunology · 2022Review
- Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans.Frontiers in immunology · 2022Review
- Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- De-coding genetic risk variants in type 1 diabetes.Immunology and cell biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Melanie R ShapiroDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, FL, United States.
Wen-I YehDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, FL, United States.
Joshua R LongfieldDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, FL, United States.
John GallagherDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, FL, United States.
Caridad M InfanteDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, FL, United States.
Sarah WellfordDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, FL, United States.
Amanda L PosgaiDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, FL, United States.
Mark A AtkinsonDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, FL, United States.
Martha Campbell-ThompsonDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, FL, United States.
Scott M LiebermanStead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, United States.
David V SerrezeThe Jackson Laboratory, Bar Harbor, ME, United States.
Aron M GeurtsDepartment of Physiology, Medical College of Wisconsin, Milwaukee, WI, United States.
Yi-Guang ChenDepartment of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, United States.
Todd M BruskoDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida Diabetes Institute, Gainesville, FL, United States.
University of Florida · USMedical College of Wisconsin · USJackson Laboratory · USUniversity of Iowa · US
Funding
Project 3P01AI042288 · NIAID · UNIVERSITY OF FLORIDA · PI Todd Michael Brusko · 1997 to 2026
$32.9MDiabetogenic Role of MHC Class I Alleles in NOD MiceR01DK046266 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V · 2000 to 2018
$7.2MB-lymphocyte Targeting Therapies for Autoimmune DiabetesR01DK095735 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V · 2013 to 2025
$6.2MMechanistic and Therapeutic Role of the CD137-CD137L Axis in Type 1 DiabetesR01DK107541 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI CHEN, YI-GUANG, RIDGWAY, WILLIAM M · 2016 to 2025
$5.6MThe CD226 costimulatory axis in type 1 diabetesR01DK106191 · NIDDK · UNIVERSITY OF FLORIDA · PI Todd Michael Brusko · 2016 to 2026
$4.4MDiscovery and Functional Studies of Genes for T1D GWAS Susceptibility LociDP3DK097605 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI CHEN, YI-GUANG, GEURTS, ARON M · 2012 to 2012
$4.3MCytokines driving T cell dysregulation in lacrimal gland autoimmunityR01EY027731 · NEI · UNIVERSITY OF IOWA · PI LIEBERMAN, SCOTT MATTHEW · 2018 to 2022
$2.4MInterdisciplinary Graduate Program in Type 1 Diabetes and Biomedical EngineeringT32DK108736 · NIDDK · UNIVERSITY OF FLORIDA · PI MARK A. ATKINSON, Benjamin George Keselowsky · 2017 to 2026
$1.9MShaping diabetogenic T cells by IL-27 in type 1 diabetesR01DK121747 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI CHEN, YI-GUANG · 2019 to 2022
$1.5MGenetic analysis of islet-infiltrating IL-21-expressing CD4 T cells in type 1 diabetesR21AI144360 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI CHEN, YI-GUANG · 2020 to 2021
$418kRoles of the Insulin-like Growth Factor Axis in Pre-Type 1 Diabetes Immune RegulationF31DK117548 · NIDDK · UNIVERSITY OF FLORIDA · PI SHAPIRO, MELANIE R · 2018 to 2019
$73kNEI NIH HHS R01 EY027731NIAID NIH HHS P01 AI042288NIAID NIH HHS R21 AI144360NIDDK NIH HHS DP3 DK097605NIDDK NIH HHS F31 DK117548NIDDK NIH HHS R01 DK046266NIDDK NIH HHS R01 DK095735NIDDK NIH HHS R01 DK106191NIDDK NIH HHS R01 DK107541NIDDK NIH HHS R01 DK121747NIDDK NIH HHS T32 DK108736
Abstract
The costimulatory molecule CD226 is highly expressed on effector/memory T cells and natural killer cells. Costimulatory signals received by T cells can impact both central and peripheral tolerance mechanisms. Genetic polymorphisms in
Indexed as
AnimalsAntigens, Differentiation, T-LymphocyteCD5 AntigensCD8-Positive T-LymphocytesCell DifferentiationCells, CulturedDiabetes Mellitus, Type 1Disease Models, AnimalGene Expression RegulationGlucose-6-PhosphataseHumansImmunodominant EpitopesImmunologic MemoryLymphocyte ActivationMiceMice, Inbred NODAntigens, Differentiation, T-LymphocyteCD5 AntigensG6pc2 protein, mouseGlucose-6-PhosphataseImmunodominant EpitopesReceptors, Antigen, T-CellT Lineage-Specific Activation Antigen 1CD226CD8+ T cellscostimulatory receptorsSjögren’s diseasetype 1 diabetes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.